Choice of Generic versus Brand-Name Antidepressants in a Regulated Prescription Drug Market: Evidence from Taiwan

被引:0
|
作者
Liu, Ya-Ming [1 ]
Ou, Huang-Tz [2 ]
Yang, Yen-Kuang [3 ]
机构
[1] Natl Cheng Kung Univ, Dept Econ, Tainan 701, Taiwan
[2] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Tainan 701, Taiwan
[3] Natl Cheng Kung Univ, Dept Psychiat, Coll Med, Tainan 701, Taiwan
来源
关键词
PHARMACEUTICAL MARKET; PHYSICIAN; IMPACT;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: A health care system in which there is no separation between prescription and dispensation, combined with a regulated prescription drug market, leads to various generic substitution mechanisms for antidepressants. Aims of the Study: We investigated the determinants of generic versus brand-name antidepressant choices in a regulated prescription market where physicians both prescribe and dispense drugs. Methods: Using data from a sample of one million individuals selected randomly from the registry of National Health Insurance beneficiaries in 2010, and all claims for these one million enrollees between January 1997 and December 2011, we employed logistic regression to examine the choice of generic versus brand-name antidepressants in the Taiwanese prescription drug market. Results: Access to various antidepressant brands varies according to the accreditation level and type of ownership of the healthcare provider. Private healthcare providers and those with lower accreditation levels were more likely to prescribe generic antidepressants compared to their brand-name counterparts. The diversity of products and competition in the molecule market was positively associated with the probability of prescribing generic antidepressants. Discussion: In a regulated prescription drug market with no separation between prescription and dispensation, the substitution of generic antidepressant prescriptions in place of brand-name prescriptions is likely driven by drug and provider market characteristics, rather than by lowering costs. Implications for Healthcare Provision: The allocation of different types of ownership and accreditation levels of healthcare providers may lead to unequal access to various brands of antidepressants. Implications for Health Policies: Policies for improving the treatment of depression should take into account the structure of molecule and provider markets as important factors in determining the choice and utilization of antidepressants, in a healthcare system where physicians both prescribe and dispense drugs. Implications for Future Research: Other psychotropic drug classes should be investigated to explore the effect of molecule and provider characteristics on the utilization of various classes of medication.
引用
收藏
页码:163 / 172
页数:10
相关论文
共 50 条
  • [31] Generic script share and the price of brand-name drugs: the role of consumer choice
    Rizzo, John A.
    Zeckhauser, Richard
    INTERNATIONAL JOURNAL OF HEALTH CARE FINANCE & ECONOMICS, 2009, 9 (03): : 291 - 316
  • [32] Generic script share and the price of brand-name drugs: the role of consumer choice
    John A. Rizzo
    Richard Zeckhauser
    International Journal of Health Care Finance and Economics, 2009, 9 : 291 - 316
  • [33] Safety of Overnight Switch from Brand-Name to Generic Levetiracetam
    Vari, Maria Stella
    Pinto, Francesca
    Mencaroni, Elisabetta
    Giudizioso, Giovanna
    Minetti, Carlo
    La Neve, Angela
    Francavilla, Tiziana
    Piccioli, Marta
    Striano, Salvatore
    del Gaudio, Luigi
    Tovo, Pierangelo
    Striano, Pasquale
    Verrotti, Alberto
    CLINICAL DRUG INVESTIGATION, 2016, 36 (01) : 87 - 91
  • [34] The impact of generic drug competition on brand name market shares - Evidence from micro data
    Aronsson, T
    Bergman, MA
    Rudholm, N
    REVIEW OF INDUSTRIAL ORGANIZATION, 2001, 19 (04) : 425 - 435
  • [35] The Impact of Generic Drug Competition on Brand Name Market Shares – Evidence from Micro Data
    Thomas Aronsson
    Mats A. Bergman
    Niklas Rudholm
    Review of Industrial Organization, 2001, 19 (4) : 423 - 433
  • [36] Safety of Overnight Switch from Brand-Name to Generic Levetiracetam
    Maria Stella Vari
    Francesca Pinto
    Elisabetta Mencaroni
    Giovanna Giudizioso
    Carlo Minetti
    Angela La Neve
    Tiziana Francavilla
    Marta Piccioli
    Salvatore Striano
    Luigi del Gaudio
    Pierangelo Tovo
    Pasquale Striano
    Alberto Verrotti
    Clinical Drug Investigation, 2016, 36 : 87 - 91
  • [37] Prescription of Brand-Name Medications When Generic Alternatives Are Available-Patently Unfair
    Gellad, Walid F.
    Good, Chester B.
    JAMA INTERNAL MEDICINE, 2016, 176 (09) : 1323 - 1324
  • [38] Converting patients from brand-name clozapine to generic clozapine
    Sajbel, TA
    Carter, GW
    Wiley, RB
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (03) : 281 - 284
  • [39] Comparison of the effectiveness of brand-name and generic antipsychotic drugs for treating patients with schizophrenia in Taiwan
    Hsu, Chih-Wei
    Lee, Sheng-Yu
    Wang, Liang-Jen
    SCHIZOPHRENIA RESEARCH, 2018, 193 : 107 - 113
  • [40] Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: evidence from Belgian prescription data
    Maria-Isabel Farfan-Portet
    Carine Van de Voorde
    France Vrijens
    Robert Vander Stichele
    The European Journal of Health Economics, 2012, 13 : 301 - 313